Metosartan CH 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes sodium and water excretion, reducing blood volume and peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing cardiac workload. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased systemic vascular resistance. The combined pharmacological actions of these agents provide complementary mechanisms to effectively manage hypertension, reduce the risk of cardiovascular events, and improve patient outcomes. Metosartan CH 25 Tablet ER is indicated for patients requiring multi-drug therapy to achieve optimal blood pressure control. It should be administered under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes. Caution is advised in patients with renal impairment, electrolyte imbalances, or contraindications to any component.